News

Panel Backs FDA Pulling Plug on Avastin


 

The company issued a statement after the meeting expressing its disappointment and avowing that it remains “ready to collaborate with the FDA to find a solution that is in the best interest of patients who need Avastin.”

Pages

Recommended Reading

Platinum Monotherapy Active Against Metastatic Triple-Negative Breast Cancer
MDedge Hematology and Oncology
Iniparib Loses Blockbuster Image in Triple-Negative Breast Cancer
MDedge Hematology and Oncology
Iniparib Loses Blockbuster Image in Triple-Negative Breast Cancer
MDedge Hematology and Oncology
Improving Weight, Exercise, Drinking May Cut Breast Cancer Risk
MDedge Hematology and Oncology
Cancer Approval Standards at Stake in Avastin Hearing
MDedge Hematology and Oncology
Video Preview: FDA Hearing on Avastin
MDedge Hematology and Oncology
Video Report: CDER Stands by Position on Avastin
MDedge Hematology and Oncology
Preview: FDA Hearing on Avastin Continues
MDedge Hematology and Oncology
Plans for New Confirmatory Trial Attacked at Avastin Hearing
MDedge Hematology and Oncology
Video Report: Genentech Defends Its Position on Avastin
MDedge Hematology and Oncology